Autor según el artículo: Torres-Fuentes C; Pastor-Cavada E; Cano R; Kandil D; Shanahan R; Juan R; Shaban H; McGlacken GP; Schellekens H
Departamento: Bioquímica i Biotecnologia
Autor/es de la URV: Torres Fuentes, Cristina
Palabras clave: Quinolones Japanese patients Ghs-r1a receptor Ghs-r1a Ghrelin G-protein Food-intake Double-blind Cell lung-cancer Cachexia C-3 position Bias Anamorelin ono-7643 Agonist ghs-r1a ghrelin cachexia
Resumen: © 2018 by the authors. Licensee MDPI, Basel, Switzerland. Cachexia is a metabolic wasting disorder characterized by progressive weight loss, muscle atrophy, fatigue, weakness, and appetite loss. Cachexia is associated with almost all major chronic illnesses including cancer, heart failure, obstructive pulmonary disease, and kidney disease and significantly impedes treatment outcome and therapy tolerance, reducing physical function and increasing mortality. Current cachexia treatments are limited and new pharmacological strategies are needed. Agonists for the growth hormone secretagogue (GHS-R1a), or ghrelin receptor, prospectively regulate the central regulation of appetite and growth hormone secretion, and therefore have tremendous potential as cachexia therapeutics. Non-peptide GHS-R1a agonists are of particular interest, especially given the high gastrointestinal degradation of peptide-based structures, including that of the endogenous ligand, ghrelin, which has a half-life of only 30 min. However, few compounds have been reported in the literature as non-peptide GHS-R1a agonists. In this paper, we investigate the in vitro potential of quinolone compounds to modulate the GHS-R1a in both transfected human cells and mouse hypothalamic cells. These chemically synthesized compounds demonstrate a promising potential as GHS-R1a agonists, shown by an increased intracellular calcium influx. Further studies are now warranted to substantiate and exploit the potential of these novel quinolone-based compounds as orexigenic therapeutics in conditions of cachexia and other metabolic and eating disorders.
Áreas temáticas: Zootecnia / recursos pesqueiros Spectroscopy Saúde coletiva Química Psicología Physical and theoretical chemistry Organic chemistry Odontología Nutrição Molecular biology Medicine (miscellaneous) Medicina veterinaria Medicina iii Medicina ii Medicina i Materiais Interdisciplinar Inorganic chemistry Geociências Farmacia Engenharias iv Engenharias ii Engenharias i Educação física Computer science applications Ciências biológicas iii Ciências biológicas ii Ciências biológicas i Ciências ambientais Ciências agrárias i Ciência de alimentos Ciência da computação Chemistry, multidisciplinary Catalysis Biotecnología Biodiversidade Biochemistry & molecular biology Astronomia / física
Acceso a la licencia de uso: https://creativecommons.org/licenses/by/3.0/es/
ISSN: 14220067
Direcció de correo del autor: cristina.torres@urv.cat
Identificador del autor: 0000-0002-2917-6910
Fecha de alta del registro: 2024-09-07
Versión del articulo depositado: info:eu-repo/semantics/publishedVersion
Enlace a la fuente original: https://www.mdpi.com/1422-0067/19/6/1605
URL Documento de licencia: https://repositori.urv.cat/ca/proteccio-de-dades/
Referencia al articulo segun fuente origial: International Journal Of Molecular Sciences. 19 (6):
Referencia de l'ítem segons les normes APA: Torres-Fuentes C; Pastor-Cavada E; Cano R; Kandil D; Shanahan R; Juan R; Shaban H; McGlacken GP; Schellekens H (2018). Quinolones modulate ghrelin receptor signaling: Potential for a novel small molecule scaffold in the treatment of cachexia. International Journal Of Molecular Sciences, 19(6), -. DOI: 10.3390/ijms19061605
DOI del artículo: 10.3390/ijms19061605
Entidad: Universitat Rovira i Virgili
Año de publicación de la revista: 2018
Tipo de publicación: Journal Publications